+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Aurobindo Pharma Ltd (AUROPHARMA) - Financial and Strategic SWOT Analysis Review

Aurobindo Pharma Ltd (AUROPHARMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Aurobindo Pharma Ltd (Aurobindo), is a vertically integrated pharmaceutical company. Its primary activities include the discovery, development, and commercialization of pharmaceutical products. The company’s product portfolio includes Semi-Synthetic Penicillin (SSP), non-penicillins, cephalosporins, and non-cephalosporins, among others. The company's products are used in various therapeutic segments such as neurosciences, cardiovascular, anti-retroviral, anti-diabetics, gastroenterology, and antibiotics. Aurobindo Pharma serves a global customer base, including multinational companies, and caters to their formulation manufacturing needs. The company operates through a network of alliances and partnerships across the globe. It operates manufacturing facilities in India, Brazil, Portugal and the US; and R&D facilities in India and the US. Aurobindo is headquartered in Hyderabad, Telangana, India.

Aurobindo Pharma Ltd Key Recent Developments

  • Aug 15, 2024: Aurobindo Pharma Receives a Warning Letter from FDA for its Hyderabad, India Facility
  • Aug 06, 2024: US FDA Inspection At Unit II Of Eugia Pharma Specialities
  • Jun 27, 2024: Classification of US FDA Inspection at the Injectable Facility of Eugia SEZ
  • May 25, 2024: Aurobindo Pharma announces Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2024.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Aurobindo Pharma Ltd - Key Facts
  • Aurobindo Pharma Ltd - Key Employees
  • Aurobindo Pharma Ltd - Key Employee Biographies
  • Aurobindo Pharma Ltd - Major Products and Services
  • Aurobindo Pharma Ltd - History
  • Aurobindo Pharma Ltd - Company Statement
  • Aurobindo Pharma Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Aurobindo Pharma Ltd - Business Description
  • Business Segment: API Business
  • Overview
  • Performance
  • Business Segment: ARV Formulations
  • Overview
  • Performance
  • Key Stats
  • Business Segment: EU Formulations
  • Overview
  • Performance
  • Business Segment: Growth Markets Formulations
  • Overview
  • Performance
  • Business Segment: US Formulations
  • Overview
  • Performance
  • Key Stats
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: India
  • Performance
  • Geographical Segment: Rest of the World
  • Performance
  • Geographical Segment: USA
  • Performance
  • R&D Overview
  • Aurobindo Pharma Ltd - Corporate Strategy
  • Aurobindo Pharma Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Aurobindo Pharma Ltd - Strengths
  • Aurobindo Pharma Ltd - Weaknesses
  • Aurobindo Pharma Ltd - Opportunities
  • Aurobindo Pharma Ltd - Threats
  • Aurobindo Pharma Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Aurobindo Pharma Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 15, 2024: Aurobindo Pharma Receives a Warning Letter from FDA for its Hyderabad, India Facility
  • Aug 06, 2024: US FDA Inspection At Unit II Of Eugia Pharma Specialities
  • Jun 27, 2024: Classification of US FDA Inspection at the Injectable Facility of Eugia SEZ
  • May 25, 2024: Aurobindo Pharma announces Audited Financial Results of the Company for the fourth quarter and year ended March , 2024.
  • May 13, 2024: Aurobindo Pharma Receives an Form 483 for its dose Manufacturing Facility in Bhiwadi, India
  • Apr 07, 2024: Aurobindo Pharma Announces Change in Senior Management
  • Mar 31, 2024: Commissioning of Four Manufacturing Facilities, Including Penicillin-G Facility, Through Wholly Owned Subsidiaries
  • Mar 28, 2024: Aurobindo Pharma Announces expansion of biologics manufacturing facilities and enter into contract manufacturing operations (“CMO”) for biologicals
  • Mar 27, 2024: Aurobindo Pharma Announces Change in Directorate
  • Mar 12, 2024: Restarting of Distribution of Aseptic Products, That Was Temporarily Stopped, Manufactured At Unit III of Eugia Pharma Specialities
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Aurobindo Pharma Ltd, Key Facts
  • Aurobindo Pharma Ltd, Key Employees
  • Aurobindo Pharma Ltd, Key Employee Biographies
  • Aurobindo Pharma Ltd, Major Products and Services
  • Aurobindo Pharma Ltd, History
  • Aurobindo Pharma Ltd, Other Locations
  • Aurobindo Pharma Ltd, Subsidiaries
  • Aurobindo Pharma Ltd, Joint Venture
  • Aurobindo Pharma Ltd, Key Competitors
  • Aurobindo Pharma Ltd, Ratios based on current share price
  • Aurobindo Pharma Ltd, Annual Ratios
  • Aurobindo Pharma Ltd, Interim Ratios
  • Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Aurobindo Pharma Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Aurobindo Pharma Ltd, Performance Chart (2020 - 2024)
  • Aurobindo Pharma Ltd, Ratio Charts
  • Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Viatris Inc
  • Emcure Pharmaceuticals Ltd
  • Dr. Reddy's Laboratories Ltd
  • Divi's Laboratories Ltd
  • Alkem Laboratories Ltd
  • Torrent Pharmaceuticals Ltd
  • Sun Pharmaceutical Industries Ltd
  • Lupin Ltd
  • Zydus Lifesciences Ltd
  • Cipla Ltd